Koyfin Home > Directory > Health Care > Acorda Therapeutics > Capital Expenditures

Acorda Therapeutics Capital Expenditures Chart (ACOR)

Acorda Therapeutics annual/quarterly Capital Expenditures from 2010 to 2020.
  • Acorda Therapeutics Capital Expenditures for the quarter ending June 06, 2020 was $-2m a -868.34% increase of 17m year over year
  • Acorda Therapeutics Capital Expenditures for the last 12 months ending June 06, 2020 was $-37m a -133.28% increase of 50m year over year
  • Acorda Therapeutics Annual Capital Expenditures for 2019 was $-90m a 63.14% decrease of -57m from 2018
  • Acorda Therapeutics Annual Capital Expenditures for 2018 was $-33m a 58.93% decrease of -20m from 2017
  • Acorda Therapeutics Annual Capital Expenditures for 2017 was $-14m a 54.76% decrease of -7m from 2016
Other Cash Flow Metrics:
  • Acorda Therapeutics Cash Flow from Operations for the quarter ending September 09, 2018 was $78m a 23.00% increase of 18m year over year
  • Acorda Therapeutics Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $60m a 1.90% increase of 1m year over year
  • Acorda Therapeutics Total Revenue for the quarter ending December 12, 2018 was $69m a -53.52% decrease of -37m year over year
View Chart On Koyfin

Quarterly ACOR Capital Expenditures Data

06/2020$-2m
03/2020$-2m
12/2019$-14m
09/2019$-19m
06/2019$-33m
03/2019$-25m
12/2018$-11m
09/2018$-12m
06/2018$-6m
03/2018$-5m

Annual ACOR Capital Expenditures Data

2019$-90m
2018$-33m
2017$-14m
2016$-6m
2015$-6m
2014$-5m
2013$-4m
2012$-10m
2011$-2m
2010$-2m